Category: Targeted Therapy
A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in Advanced Refractory Solid Tumors
Study Name A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in Advanced Refractory Solid Tumors…
Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of care therapy alone for advanced HER2 positive biliary tract cancer
Study Name Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard…
FIRST-308
Study Name FIRST-308 ClinicalTrials.gov Identifier (if applicable) NCT05948475 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted…
Safety and Tolerability of TNG462 in Patients with MTAP-deleted Solid Tumors
Study Name Safety and Tolerability of TNG462 in Patients with MTAP-deleted Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT05732831 Clinical Trial Category (check…
Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors
Study Name Safety and Tolerability of TNG908 in Patients with MTAP-deleted Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT05275478 Clinical Trial…
phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ)
Study Name A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies…
Brightline-2
Study Name Brightline-2 ClinicalTrials.gov Identifier (if applicable) NCT05512377 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study…
A Study to Evaluate KIN-3248 (study drug) in Patients with Advanced Tumors Who Have FGFR2 and//or FGFR3 Gene Alterations
Study Name A Study to Evaluate KIN-3248 (study drug) in Patients with Advanced Tumors Who Have FGFR2 and//or FGFR3 Gene…
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Study Name A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid…
ZW25-201: A Phase 2 Study of Zanidatamab (ZW25; bispecific antibody) Plus First-line Chemotherapy in HER2-Expressing Cancers, Including Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, and Colorectal Cancer
Study Name ZW25-201: A Phase 2 Study of Zanidatamab (ZW25; bispecific antibody) Plus First-line Chemotherapy in HER2-Expressing Cancers, Including Cholangiocarcinoma…